NCT06649344

A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes

← Hub

Registry fields

Overall status: COMPLETED
Conditions: Type 2 Diabetes
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: HRS9531 Injection, Semaglutide Injection
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. (INDUSTRY)

Cached at: 2026-07-31 05:28:25

View on ClinicalTrials.gov

Brief summary

The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for 36 weeks and 52 weeks.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report